Join to View Full Profile
331 Panorama DriveSan Francisco, CA 94131
Phone+1 415-297-6428
Dr. Sehnert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Pediatric Cardiology, 1995 - 1999
University of ColoradoResidency, Pediatrics, 1992 - 1995
University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
CA State Medical License 1995 - 2025
Clinical Trials
- Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial Start of enrollment: 2007 Jan 01
- MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy Start of enrollment: 2010 Jun 01
- Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Start of enrollment: 2018 May 29
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsEffect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.Sharon Cresci, Richard G Bach, Sara Saberi, Anjali T Owens, John A Spertus
Circulation. 2024-02-13 - 4 citationsPatient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.Konstantinos C Siontis, Sean Abreau, Zachi I Attia, Joshua P Barrios, Thomas A Dewland
JACC. Advances. 2023-10-01 - 38 citationsDose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.Milind Y Desai, Anjali Owens, Jeffrey B Geske, Kathy Wolski, Sara Saberi
Circulation. 2023-03-14
Press Mentions
- Using AI in Electrocardiogram Analysis Can Improve Diagnosis and Treatment of Hypertrophic CardiomyopathyMarch 7th, 2022
- Results from Two Phase 3 Studies Evaluating CAMZYOS (Mavacamten) for Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Released by Bristol Myers SquibbSeptember 6th, 2023
- Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy ReleasedSeptember 10th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
